Elizabeth R Kessler1,2, S Gail Eckhardt1,2, Todd M Pitts1,2, Erica L Bradshaw-Pierce2,3, Cindy L O'byrant4, Wells A Messersmith1,2, Sujatha Nallapreddy1,2, Colin Weekes1,2, Jennifer Spratlin5, Christopher H Lieu1,2, Madeleine A Kane1,2, Sarah Eppers2, Elizabeth Freas2, Stephen Leong6,7. 1. Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, MS 8117, 12801 E 17th Avenue, Room 8120, Aurora, CO, 80045, USA. 2. University of Colorado Cancer Center, Aurora, Colorado, USA. 3. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy, Aurora, CO, USA. 4. Department of Clinical Pharmacy, Skaggs School of Pharmacy, Aurora, CO, USA. 5. Department of Oncology, University of Alberta, Edmonton, AB, Canada. 6. Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, MS 8117, 12801 E 17th Avenue, Room 8120, Aurora, CO, 80045, USA. stephen.leong@ucdenver.edu. 7. University of Colorado Cancer Center, Aurora, Colorado, USA. stephen.leong@ucdenver.edu.
Abstract
BACKGROUND: Vandetanib is a multitargeted tyrosine kinase inhibitor that affects vascular endothelial growth factor receptor (VEGF), epidermal growth factor (EGF), and rearranged during transfection (RET) mediated receptors which are important for growth and invasion of biliary and pancreatic cancers. This phase I study evaluated the safety profile of vandetanib in combination with standard doses of gemcitabine and capecitabine in order to determine the maximum tolerated dose (MTD). METHODS: In this single center phase I trial, patients received gemcitabine intravenously (i.v.) at 1000 mg/m2 days 1, 8, 15 in a 28 day cycle, capecitabine orally at 850 mg/m2 twice daily on days 1-21, and escalating doses of vandetanib (200 or 300 mg orally daily). Once the MTD was defined, an expansion cohort of patients with advanced biliary cancers and locally advanced or metastatic pancreatic cancer was enrolled. Blood samples were also collected at predetermined time points for biomarker analysis. RESULTS: Twenty-three patients were enrolled: 9 in the dose escalation and 14 in the dose expansion cohort. One dose limiting toxicity (DLT), of grade 4 neutropenia, occurred in the 200 mg vandetanib cohort. The most common adverse effects were diarrhea (39 %), nausea and vomiting (34%), and rash (33%). There were 3 partial responses and stable disease of >2 months (range 2-45, median 5) was observed in 15/23 patients. There was no association between changes in biomarker analytes and disease response. CONCLUSION: The combination of gemcitabine, capecitabine and vandetanib is well tolerated at the recommended phase II dose of gemcitabine 1000 mg/m2 weekly for three consecutive weeks, capecitabine 850 mg/m2 BID days 1-21, and vandetanib 300 mg daily, every 28 days. This combination demonstrated promising activity in pancreaticobiliary cancers and further evaluation is warranted in these diseases. NCT00551096.
BACKGROUND: Vandetanib is a multitargeted tyrosine kinase inhibitor that affects vascular endothelial growth factor receptor (VEGF), epidermal growth factor (EGF), and rearranged during transfection (RET) mediated receptors which are important for growth and invasion of biliary and pancreatic cancers. This phase I study evaluated the safety profile of vandetanib in combination with standard doses of gemcitabine and capecitabine in order to determine the maximum tolerated dose (MTD). METHODS: In this single center phase I trial, patients received gemcitabine intravenously (i.v.) at 1000 mg/m2 days 1, 8, 15 in a 28 day cycle, capecitabine orally at 850 mg/m2 twice daily on days 1-21, and escalating doses of vandetanib (200 or 300 mg orally daily). Once the MTD was defined, an expansion cohort of patients with advanced biliary cancers and locally advanced or metastatic pancreatic cancer was enrolled. Blood samples were also collected at predetermined time points for biomarker analysis. RESULTS: Twenty-three patients were enrolled: 9 in the dose escalation and 14 in the dose expansion cohort. One dose limiting toxicity (DLT), of grade 4 neutropenia, occurred in the 200 mg vandetanib cohort. The most common adverse effects were diarrhea (39 %), nausea and vomiting (34%), and rash (33%). There were 3 partial responses and stable disease of >2 months (range 2-45, median 5) was observed in 15/23 patients. There was no association between changes in biomarker analytes and disease response. CONCLUSION: The combination of gemcitabine, capecitabine and vandetanib is well tolerated at the recommended phase II dose of gemcitabine 1000 mg/m2 weekly for three consecutive weeks, capecitabine 850 mg/m2 BID days 1-21, and vandetanib 300 mg daily, every 28 days. This combination demonstrated promising activity in pancreaticobiliary cancers and further evaluation is warranted in these diseases. NCT00551096.
Authors: W Scheithauer; B Schüll; H Ulrich-Pur; K Schmid; M Raderer; K Haider; W Kwasny; D Depisch; B Schneeweiss; F Lang; G V Kornek Journal: Ann Oncol Date: 2003-01 Impact factor: 32.976
Authors: Viviane Hess; Marc Salzberg; Markus Borner; Rudolf Morant; Arnaud D Roth; Christian Ludwig; Richard Herrmann Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Kathy D Miller; Jose Manuel Trigo; Catherine Wheeler; Alan Barge; Jacqui Rowbottom; George Sledge; Jose Baselga Journal: Clin Cancer Res Date: 2005-05-01 Impact factor: 12.531
Authors: Stephen R Wedge; Donald J Ogilvie; Michael Dukes; Jane Kendrew; Rosemary Chester; Janet A Jackson; Sarah J Boffey; Paula J Valentine; Jon O Curwen; Helen L Musgrove; George A Graham; Gareth D Hughes; Andrew P Thomas; Elaine S E Stokes; Brenda Curry; Graham H P Richmond; Peter F Wadsworth; Alison L Bigley; Laurent F Hennequin Journal: Cancer Res Date: 2002-08-15 Impact factor: 12.701